Published in Neurology on November 05, 2008
Mechanisms of genomic instabilities underlying two common fragile-site-associated loci, PARK2 and DMD, in germ cell and cancer cell lines. Am J Hum Genet (2010) 1.10
Neuropsychological Profile of Parkin Mutation Carriers with and without Parkinson Disease: The CORE-PD Study. J Int Neuropsychol Soc (2010) 1.04
Self-report of cognitive impairment and mini-mental state examination performance in PRKN, LRRK2, and GBA carriers with early onset Parkinson's disease. J Clin Exp Neuropsychol (2010) 1.03
Cognitive and motor function in long-duration PARKIN-associated Parkinson disease. JAMA Neurol (2014) 0.95
Phenotype analysis in patients with early onset Parkinson's disease with and without parkin mutations. J Neurol (2011) 0.89
Parkin and PINK1 parkinsonism may represent nigral mitochondrial cytopathies distinct from Lewy body Parkinson's disease. Parkinsonism Relat Disord (2009) 0.87
Parkinson disease(s): is "Parkin disease" a distinct clinical entity? Neurology (2008) 0.86
Altered hippocampal synaptic physiology in aged parkin-deficient mice. Neuromolecular Med (2010) 0.80
The relation between depression and parkin genotype: the CORE-PD study. Parkinsonism Relat Disord (2011) 0.80
Variable phenotypic expression in families with early-onset Parkinsonism due to PRKN mutations. J Neurol (2014) 0.78
Understanding the susceptibility of dopamine neurons to mitochondrial stressors in Parkinson's disease. FEBS Lett (2015) 0.78
The relationship between obsessive-compulsive symptoms and PARKIN genotype: The CORE-PD study. Mov Disord (2014) 0.77
A Peruvian family with a novel PARK2 mutation: Clinical and pathological characteristics. Parkinsonism Relat Disord (2015) 0.76
Brain Connectivity Changes in Autosomal Recessive Parkinson Disease: A Model for the Sporadic Form. PLoS One (2016) 0.75
The Monoamine Brainstem Reticular Formation as a Paradigm for Re-Defining Various Phenotypes of Parkinson's Disease Owing Genetic and Anatomical Specificity. Front Cell Neurosci (2017) 0.75
CSF Biomarkers and Its Associations with 18F-AV133 Cerebral VMAT2 Binding in Parkinson's Disease-A Preliminary Report. PLoS One (2016) 0.75
Neuromelanin MRI is useful for monitoring motor complications in Parkinson's and PARK2 disease. J Neural Transm (Vienna) (2017) 0.75
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature (1998) 21.49
Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med (2000) 4.98
Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain (2007) 3.62
Parkin disease: a phenotypic study of a large case series. Brain (2003) 2.41
Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurol (2007) 2.40
Proposed dose equivalence for rapid switch between dopamine receptor agonists in Parkinson's disease: a review of the literature. Clin Ther (2006) 1.71
Parkin mutations are frequent in patients with isolated early-onset parkinsonism. Brain (2003) 1.68
Alpha-synuclein and Parkinson's disease. Cell Mol Life Sci (2000) 1.63
How much phenotypic variation can be attributed to parkin genotype? Ann Neurol (2003) 1.44
Complex relationship between Parkin mutations and Parkinson disease. Am J Med Genet (2002) 1.44
Positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial parkinsonism associated with mutations in the parkin gene. Ann Neurol (2001) 1.42
Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study. Brain (2002) 1.30
Clinical analysis of 17 patients in 12 Japanese families with autosomal-recessive type juvenile parkinsonism. Neurology (1996) 1.26
Striatal and cortical pre- and postsynaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism. Brain (2004) 1.16
Dopa-responsive dystonia: [18F]dopa positron emission tomography. Ann Neurol (1991) 1.13
Coding polymorphisms in the parkin gene and susceptibility to Parkinson disease. Arch Neurol (2003) 1.03
Rare heterozygous parkin variants in French early-onset Parkinson disease patients and controls. J Med Genet (2007) 1.02
Autosomal recessive early-onset parkinsonism with diurnal fluctuation: clinicopathologic characteristics and molecular genetic identification. Brain Dev (2000) 0.94
Parkin disease in a Brazilian kindred: Manifesting heterozygotes and clinical follow-up over 10 years. Mov Disord (2005) 0.94
The nigrostriatal dopaminergic system in familial early onset parkinsonism with parkin mutations. Neurology (2001) 0.91
Deletion of the parkin and PACRG gene promoter in early-onset parkinsonism. Hum Mutat (2007) 0.90
Clinical, 18F-dopa PET, and genetic analysis of an ethnic Chinese kindred with early-onset parkinsonism and parkin gene mutations. Mov Disord (2002) 0.87
Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature (2001) 33.12
Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology (2005) 21.67
Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science (1996) 11.59
Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet (2013) 9.46
Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology (1996) 8.82
Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA (2001) 8.72
Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med (2009) 7.53
Clinical and genetic abnormalities in patients with Friedreich's ataxia. N Engl J Med (1996) 6.57
Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology (2003) 6.51
Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology (2006) 6.44
Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med (2013) 6.37
Activation of human dendritic cells through CD40 cross-linking. J Exp Med (1994) 6.16
CARD15 mutations in Blau syndrome. Nat Genet (2001) 5.79
Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ (1999) 5.36
Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet (2004) 5.06
Mutations of SCN1A, encoding a neuronal sodium channel, in two families with GEFS+2. Nat Genet (2000) 5.05
Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med (2000) 4.98
Transient acute depression induced by high-frequency deep-brain stimulation. N Engl J Med (1999) 4.79
Spastin, a new AAA protein, is altered in the most frequent form of autosomal dominant spastic paraplegia. Nat Genet (1999) 4.74
Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med (1998) 4.72
Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. Brain (2005) 4.33
The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain (1999) 4.25
Familial hyperglycemia due to mutations in glucokinase. Definition of a subtype of diabetes mellitus. N Engl J Med (1993) 3.96
Genome-wide scan for autism susceptibility genes. Paris Autism Research International Sibpair Study. Hum Mol Genet (1999) 3.93
Long-term suppression of tremor by chronic stimulation of the ventral intermediate thalamic nucleus. Lancet (1991) 3.89
Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol Histopathol (1997) 3.80
Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology (2005) 3.45
Clinical spectrum of CADASIL: a study of 7 families. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Lancet (1995) 3.42
Behavioural disorders, Parkinson's disease and subthalamic stimulation. J Neurol Neurosurg Psychiatry (2002) 3.41
Chronic electrical stimulation of the ventralis intermedius nucleus of the thalamus as a treatment of movement disorders. J Neurosurg (1996) 3.37
Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats. Nat Genet (1996) 3.26
First genetic evidence of GABA(A) receptor dysfunction in epilepsy: a mutation in the gamma2-subunit gene. Nat Genet (2001) 3.15
Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease. Appl Neurophysiol (1987) 3.14
Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am J Hum Genet (1999) 3.14
Predominant dystonia with marked cerebellar atrophy: a rare phenotype in familial dystonia. Neurology (2006) 3.07
Effect of parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet (1995) 3.06
LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N Engl J Med (2006) 2.93
Neurosurgery at an earlier stage of Parkinson disease: a randomized, controlled trial. Neurology (2006) 2.90
DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology (2007) 2.86
Nonsense mutation in the glucokinase gene causes early-onset non-insulin-dependent diabetes mellitus. Nature (1992) 2.86
Cloning of the SCA7 gene reveals a highly unstable CAG repeat expansion. Nat Genet (1997) 2.77
Gelatinase B functions as regulator and effector in leukocyte biology. J Leukoc Biol (2001) 2.66
Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol (1994) 2.65
Amnestic syndrome of the medial temporal type identifies prodromal AD: a longitudinal study. Neurology (2007) 2.61
Close linkage of glucokinase locus on chromosome 7p to early-onset non-insulin-dependent diabetes mellitus. Nature (1992) 2.59
Neurosurgery in Parkinson disease: a distressed mind in a repaired body? Neurology (2006) 2.59
Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain (1991) 2.52
Partially overlapping neural networks for real and imagined hand movements. Cereb Cortex (2000) 2.47
Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol (2007) 2.47
Chromosome 9p-linked families with frontotemporal dementia associated with motor neuron disease. Neurology (2009) 2.46
Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem (1989) 2.44
Estimation of the mutation frequencies in Charcot-Marie-Tooth disease type 1 and hereditary neuropathy with liability to pressure palsies: a European collaborative study. Eur J Hum Genet (1996) 2.40
Spectrum of SPG4 mutations in autosomal dominant spastic paraplegia. Hum Mol Genet (2000) 2.40
Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form. Nat Genet (1995) 2.33
Extrastriatal and striatal D(2) dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia. Br J Psychiatry (2001) 2.32
APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol Psychiatry (2011) 2.31
The mental representation of hand movements after parietal cortex damage. Science (1996) 2.28
Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem (1989) 2.26
The neural system that bridges reward and cognition in humans: an fMRI study. Proc Natl Acad Sci U S A (2002) 2.26
Bilateral subthalamic stimulation for Parkinson's disease by using three-dimensional stereotactic magnetic resonance imaging and electrophysiological guidance. J Neurosurg (2000) 2.25
Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson's disease. J Neurol Neurosurg Psychiatry (2004) 2.21
Genome-wide association study confirms BST1 and suggests a locus on 12q24 as the risk loci for Parkinson's disease in the European population. Hum Mol Genet (2010) 2.21
New variant of Creutzfeldt-Jakob disease in a 26-year-old French man. Lancet (1996) 2.20
Frequency of the DYT1 mutation in primary torsion dystonia without family history. Arch Neurol (2000) 2.17
The impact on Parkinson's disease of electrical parameter settings in STN stimulation. Neurology (2002) 2.14
Flagellin stimulation of intestinal epithelial cells triggers CCL20-mediated migration of dendritic cells. Proc Natl Acad Sci U S A (2001) 2.12
Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers. Neurology (2012) 2.12
The natural history of degenerative ataxia: a retrospective study in 466 patients. Brain (1998) 2.11
Stimulation of the subthalamic nucleus in Parkinson's disease: a 5 year follow up. J Neurol Neurosurg Psychiatry (2005) 2.08
Hallucinations, REM sleep, and Parkinson's disease: a medical hypothesis. Neurology (2000) 2.08
Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience (1996) 2.06
Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis (2004) 2.06